Alcohol effects during acamprosate treatment: a dose-response study in humans (Q44977111)

7 December 2017

title

Alcohol effects during acamprosate treatment: a dose-response study in humans (English)

1 reference

7 December 2017

2

Mary E McCaul

1 reference

7 December 2017

Susan M Brasser

1

1 reference

7 December 2017

Elisabeth J Houtsmuller

series ordinal

3

1 reference

7 December 2017

publication date

1 July 2004

1 reference

Alcoholism: Clinical and Experimental Research

7 December 2017

published in

1 reference

7 December 2017

volume

28

1 reference

7 December 2017

issue

7

1 reference

7 December 2017

page(s)

1074-1083

1 reference

Acamprosate Is Neuroprotective Against Glutamate-Induced Excitotoxicity When Enhanced by Ethanol Withdrawal in Neocortical Cultures of Fetal Rat Brain

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Acamprosate, but not naltrexone, inhibits conditioned abstinence behaviour associated with repeated ethanol administration and exposure to a plus-maze

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Effects of acamprosate on ethanol-seeking and self-administration in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Acamprosate decreases the hypermotility during repeated ethanol withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Chronic acamprosate eliminates the alcohol deprivation effect while having limited effects on baseline responding for ethanol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Potential neuroprotective effects of acamprosate

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Lack of effects of Ca-acetyl homotaurinate on chronic and acute toxicities of ethanol in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Acamprosate (calcium acetylhomotaurinate) enhances the N-methyl-D-aspartate component of excitatory neurotransmission in rat hippocampal CA1 neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Development and validation of the Biphasic Alcohol Effects Scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Alcohol and secobarbital effects as a function of familial alcoholism: extended intoxication and increased withdrawal effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Effects of acute acamprosate and homotaurine on ethanol intake and ethanol-stimulated mesolimbic dopamine release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

The anti-craving drug acamprosate reduces c-fos expression in rats undergoing ethanol withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Acamprosate reduces context-dependent ethanol effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Clinical pharmacokinetics of acamprosate

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Acamprosate and alcohol: III. Effects on alcohol discrimination in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

Acamprosate (calciumacetylhomotaurinate) decreases postsynaptic potentials in the rat neocortex: possible involvement of excitatory amino acid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000130802.07692.29

10.1097/01.ALC.0000130802.07692.29

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference